Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).

Authors

null

Jerome Galon

Laboratory of Integrative Cancer Immunology, INSERM, Paris, France

Jerome Galon , John Rossi , Sarah Turcan , Corinne Danan , Frederick Lundry Locke , Sattva Swarup Neelapu , David Bernard Miklos , Nancy L. Bartlett , Caron Alyce Jacobson , Ira Braunschweig , Tanya Siddiqi , Yi Lin , John Timmerman , Patrick Michael Reagan , Lazaros J. Lekakis , Sherryonne Unabia , William Y. Go , Jeffrey S. Wiezorek , Adrian Bot , Olalekan O. Oluwole

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research,Immunotherapy

Sub Track

Biomarkers and Correlative Studies from Immunotherapy Trials

Clinical Trial Registration Number

NCT02348216

Citation

J Clin Oncol 35, 2017 (suppl; abstr 3025)

DOI

10.1200/JCO.2017.35.15_suppl.3025

Abstract #

3025

Poster Bd #

120

Abstract Disclosures